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nerve damage induced skeletal 
muscle atrophy is associated 
with increased accumulation of 
intramuscular glucose and polyol 
pathway intermediates
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Perturbations in skeletal muscle metabolism have been reported for a variety of neuromuscular 
diseases. However, the role of metabolism after constriction injury to a nerve and the associated muscle 
atrophy is unclear. We have analyzed rat tibialis anterior (TA) four weeks after unilateral constriction 
injury to the sciatic nerve (DMG) and in the contralateral control leg (CTRL) (n = 7) to investigate 
changes of the metabolome, immunohistochemistry and protein levels. Untargeted metabolomics 
identified 79 polar metabolites, 27 of which were significantly altered in DMG compared to CTRL. 
Glucose concentrations were increased 2.6-fold in DMG, while glucose 6-phosphate (G6-P) was 
unchanged. Intermediates of the polyol pathway were increased in DMG, particularly fructose (1.7-
fold). GLUT4 localization was scattered as opposed to clearly at the sarcolemma. Despite the altered 
localization, we found GLUT4 protein levels to be increased 7.8-fold while GLUT1 was decreased 1.7-
fold in nerve damaged TA. PFK1 and GS levels were both decreased 2.1-fold, indicating an inability of 
glycolysis and glycogen synthesis to process glucose at sufficient rates. In conclusion, chronic nerve 
constriction causes increased GLUT4 levels in conjunction with decreased glycolytic activity and 
glycogen storage in skeletal muscle, resulting in accumulation of intramuscular glucose and polyol 
pathway intermediates.
Skeletal muscle atrophy is a pathological condition associated with many diseases. While protein metabolism 
is thought to be the main regulator of muscle size, many situations of atrophy and neuromuscular diseases are 
accompanied by changes to substrate metabolism as well. Critical illness myopathy (CIM) is a condition for which 
disturbances of glucose metabolism have been reported by our laboratory and others1. Specifically, we have found 
the primary glucose transporter GLUT4 to be insufficiently translocated in CIM patients, resulting in decreased 
glucose supply and reduced AMPK activity2. Besides CIM, a number of other neuromuscular disorders have been 
found to be show signs of changes to glucose metabolism in skeletal muscle such as amyotrophic lateral sclerosis 
(ALS), Charcot-Marie-Tooth neuropathy (CMT) or spinal muscular atrophy (SMA)3–5. For example, it has been 
found that concentrations of glucose as well as fructose are increased in skeletal muscle samples of ALS patients, 
often accompanied by an early onset of insulin resistance6. Early research in respect to nerve damage and glucose 
metabolism has reported that denervation is followed by insulin resistance, reduced glucose transport into the 
muscle, less glucose abundance and transiently decreased GLUT4 levels7–9. A more recent study in mice found 
that despite decreased GLUT4 mRNA abundance, long term denervation was associated with increased GLUT4 
protein levels potentially regulated by increased Akt activity10. The same study found that glucose uptake in 
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long term denervated muscle is increased compared to healthy controls10. However, data on changes to substrate 
metabolism after nerve damage are often limited to denervation via transection. By contrast, peripheral nerve 
damage in clinical practice often comprises a wide range of other injuries such as crush- or chronic constriction 
injuries11. These types of nerve injuries are clinically distinct from nerve transection and little is known on sub-
strate metabolism in those conditions. We investigated changes to substrate metabolism in rat TA four weeks after 
constriction injury of the sciatic nerve as a follow-up to previous experiments on protein metabolism in the same 
animals12. We utilized a combination of untargeted metabolomics, immunohistochemistry and western blotting 
to examine alterations and potentially underlying mechanisms.
Methods
ethical approval. All animal experiments were approved by the local authority (Landesamt für Gesundheit 
und Soziales, Berlin, Germany) under the reference G 0083/15 and performed at the animal care unit of the Max 
Delbrück Center for Molecular Medicine (MDC, Berlin). All experiments were carried out in accordance with 
local guidelines for good scientific practice and animal care.
Animals. We have previously described the constriction injury model and skeletal muscle atrophy in the 
same animals that were investigated in this study12. Briefly, male Sprague-Dawley rats (Charles River, Germany) 
between 20–21 weeks of age were housed in individual cages. The animals were fed a chow diet suited towards 
weight maintenance rather than commonly occurring, age associated weight gain. Nerve damage and muscle 
atrophy were induced via chronic constriction injury by implanting an electrode cuff around the sciatic nerve 
slightly above the point of trifurcation.
Free metabolite extraction. The free metabolite pool of muscle samples was extracted as described pre-
viously with small modifications13. Frozen tissue of rat TA (n = 7) was weighed and 20 mg of tissue per sample 
was solubilized in methanol-chloroform-water (MCW; 5:2:1) (Sigma-Aldrich, Germany), containing 2 µg/ml 
cinnamic acid (Sigma-Aldrich, Germany) as internal standard. After addition of MCW, all samples were shaken 
twice at 6000RPM for 1 min using a Precellys 24 (Bertin Technologies, France) to homogenize them. This step was 
repeated after 10 µl ddH2O * mg-1 of tissue was added to the muscle samples. For phase separation of polar and 
lipid intermediates, all samples were spun for 10 min at 20,000 g and 4 °C. The supernatant containing the polar 
phase was then collected and dried for 3 h in a SpeedVac (Thermo Scientific, Germany). For derivatization, the 
dried samples were dissolved in 20 µl methoxyamine hydrochloride solution (Sigma-Aldrich, Germany) (40 mg/
ml in pyridine [Roth, Germany]) and incubated for 90 min at 30 °C in a Thermomixer (Eppendorf, Germany). 
Subsequently, 80 µl of N-methyl-N- (trimethylsilyl)trifluoroacetamide (MSTFA) (Machery-Nagel, Germany) 
containing a retention index standard was added to the samples and incubated at 37° for 45 min. The supernatant 
was then collected and transferred into appropriate vials for GC-MS measurement.
Untargeted metabolomics. GC-TOF-MS measurements were performed as described previously14. 
Briefly, a gas chromatograph coupled to a time of flight mass spectrometer (Pegasus III- TOF-MS-System [LECO, 
USA]) was used for analysis. The samples were prepared as described in the section above and injected into the 
GC-TOF-MS in a split mode using a temperature-controlled injector (Gerstel, Germany) with a baffled glass liner 
(Gerstel, Germany). For free metabolite concentrations we used a previously established split of 1:5 and samples 
were injected once. After initially starting the injection at 80 °C for 30 s, the temperature was gradually increased 
up to 300 °C for 2 min. Gas chromatographic separation was performed on an Agilent 6890 N (Agilent, USA), 
equipped with a VF 5 ms column (Varian, USA). Helium was used as carrier gas at 1.2 ml/min flow rate. Gas 
chromatography was performed with a temperature starting at 70 °C for 2 min, gradually increasing up to 350 °C 
for 2 min. At a detector voltage of 1750 V, spectra were recorded in a mass range of 60 to 600 u with 20 spectra/s. 
The data were pre-processed with ChromaTOF (LECO, USA) including resampling, baseline subtraction and 
peak detection. Subsequently the data were read into our house intern software MAUI-VIA for annotation and 
quantification of individual metabolites, more elaborately described elsewhere15.
immunohistochemistry. Cryosections for immunohistochemistry have been prepared as described pre-
viously12. Sectioned samples were left 1 h at room temperature to dry, before being fixated in formaldehyde for 
5 min. Sections were blocked in PBS (3% BSA) for 30 min, washed and subsequently incubated with GLUT4 
(1:1000 in PBS (1% BSA), provided by A. Schürmann, DIfE Potsdam) for 1 h at room temperature. After washing, 
sections were incubated with a biotinylated secondary antibody (1:200 in PBS; Dianova, Germany) for 30 min, 
washed and incubated with Streptavidin-Cy3 (1:200 in PBS; Dianova, Germany) for 30 min. Subsequently the 
sections were washed and incubated with Hoechst (1:1000 in PBS; Thermo Fisher, Germany) for 5 min to stain for 
nuclear positioning, washed and mounted on slides using Aqua Mount (Polysciences, Germany).
Western blotting. Rat TA (n = 5) was immersed in 150 mM NaCl, 0.5% Triton X-100, 50 mM Tris, 50 mM 
NaF, 1 mM Na3VO4, 1 mM PMSF, 0.5% Na-Deoxycholate, 1 mM EDTA, and 1x cOmplete protease inhibitor 
complex (Roche, Germany) and homogenized with a pestil. After lysing the samples they were centrifuged for 
15 min (13,200 rpm) and the supernatant collected. Semi dry transfer was conducted as described previously12. 
The following antibodies were used: Dysferlin HAMLET (Novocastra, Germany), Cyclophillin A (#ab41684) 
(Abcam, UK), Akt (#9272), pAkt (#9271), AMPK (#2603), pAMPK (#2535) (Cell Signaling, USA). The sec-
ondary antibodies were applied accordingly and the membrane imaged via infrared imaging (Odyssey, LI-COR 
Biosciences, USA). We and others have previously found that normalizing protein levels to housekeeping proteins 
is less reliable than normalizing to total protein content12,16,17. We therefore normalized all levels of our proteins to 
total protein content of the gel stained with Coomassie Blue. During revisions, the same set muscle samples were 
freshly prepared according to a similar protocol as above and the sample size increased (n = 6)18. The following 
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antibodies were used: IRS1 (#2382), pan NOS (#2977), GSK3 α/β (#9331), GS (#3893), Annexin A2 (#8235), 
LC3B (#2775) (Cell Signaling, USA), GLUT1 (#7903), GLUT4 (#53566), PFK1 (#31712), Muscle LIM (CRP3) 
(#166930), eNOS/NOS III (#610296) (BD Biosciences, USA) and total OXPHOS (#MS604–300) (Abcam, UK). 
All band intensities were normalized to total protein content of the gel as assessed via stain-free technology 
(Criterion TGX Stain-Free Gels, Bio-Rad, USA).
Statistics. Groups were compared with an unpaired t test and results with a p value < 0.05 deemed statisti-
cally significant. Effect size was calculated according to Cohen: d = (M1 − M2)/SDpooled, where d is the effect size, 
M1 is the control leg and M2 the damaged leg and SDpooled the combined standard deviation of all values from both 
groups for each metabolite. Data are displayed as mean and standard deviation (SD).
Results
Altered muscle metabolism in nerve damaged TA. Rat TA (n = 7) was phase-separated and the polar 
phase, containing free intramuscular metabolites of glycolysis and amino acid metabolism, was subjected to 
untargeted metabolomics via GC-TOF-MS. We could identify 79 metabolites out of which 27 were significantly 
altered in nerve damaged TA (Fig. 1A; Supplement). Specifically, glucose metabolism appeared to be affected: 
glucose concentrations were increased 2.6-fold in the nerve damaged TA (Fig. 1B). Under physiological circum-
stances, glucose is phosphorylated to G6-P by hexokinase upon entering the cell. Therefore, increased concen-
trations of glucose would be expected to be accompanied by a concomitant increase in G6-P to feed glucose into 
glycolysis. However, G6-P appeared to be unchanged or slightly decreased rather than increased in damaged 
TA (Fig. 1B; d = 0.6). A substrate pathway which is upregulated in case of deranged or saturated glycolysis is the 
polyol pathway. Increased activity of this pathway should result in increased abundance of pathway intermediates 
and/or end products. Indeed we found that among those 27 differentially regulated metabolites in the nerve dam-
aged TA, the polyol pathway end product fructose was upregulated 1.7-fold compared to the control leg (Fig. 1B). 
The intermediate sorbitol appeared increased in the damaged TA as well, but did not reach statistical signifi-
cance (Fig. 1B). However, sorbitol could only be found and annotated in two out of seven animals in the control 
leg, indicating that concentrations in healthy muscle are below or only slightly above our detection threshold 
(Fig. 1B). In further support of the hypothesis that glucose metabolism is affected and other substrate pathways 
upregulated as a compensatory mechanism, we screened the differentially regulated metabolites for ketone bod-
ies. We found butanoic acid 3-hydroxy to be upregulated 1.8-fold in nerve damaged TA (Supplement S1).
Scattered localization of GLUT4 in nerve damaged TA. We next investigated localization of GLUT4 
by immunohistochemistry on nerve damaged rat muscle and contralateral control sections (Fig. 2). We found 
GLUT4 primarily located in the perinuclear space and unevenly distributed across damaged TA sections while in 
control sections GLUT4 was located to the sarcolemma (Fig. 2).
Elevated levels of proteins associated with membrane damage, cytoskeletal integrity and oxi-
dative activity. To investigate the underlying molecular changes of the observed structural damage to the 
muscle we performed western blot analysis. We found dysferlin, a big structural protein and a mediator of mem-
brane repair, to be upregulated 4.5-fold in damaged TA (Fig. 3A,B). Annexin A2 is a protein involved in linkage 
of membrane proteins to the actin complex and closely associated with Dysferlin19. Annexin A2 was increased 
3.3-fold in damaged TA compared to healthy controls (Fig. 3A,C). Cyclophilin A (CyPA) is a damage associated 
protein which is thought to contribute to inflammation and cell death and was found to be upregulated 11-fold 
in nerve damaged TA compared to the contralateral control (Fig. 3A,B). Muscle LIM (CRP3) has been shown 
to be involved in cytoskeletal integrity of the contractile apparatus by organizing and connecting myofibrils and 
interacting with proteins in the z-disc of sarcomeres, as well as a potential role in autophagy20,21. Muscle LIM was 
increased 9.8-fold in nerve damaged TA (Fig. 3A,C). In line with the potential role of Muscle LIM in autophagy, 
we found LC3B levels to be 4-fold increased with nerve damage (Fig. 3A,C). Interestingly, NOS (pan) levels were 
reduced 3.2-fold with nerve damage, indicating decreased oxidative activity (Fig. 3A,C). This is in contrast to the 
metabolomics data which indicated upregulated oxidative activity through increased polyol pathway utilization. 
All bands on the membrane (Fig. 3B,C) were normalized to total protein content per corresponding lane on the 
gel (Supplement S2 and S3) as described previously12,16–18.
Increased glucose concentrations are accompanied by increased GLUT4 levels, but decreased 
glycolysis and glycogen synthesis. Nerve damage caused a 4.8-fold decrease in IRS1 signaling 
(Fig. 4A,C). Interestingly, despite this decrease, total- and pAkt levels were found to be increased 3-fold and 
1.5-fold respectively (Fig. 4A,B). The scattered localization of GLUT4 found in Fig. 2 does not seem to impact 
GLUT4 protein levels, as GLUT4 was increased 7.8-fold in nerve damaged TA while GLUT1 was decreased 
1.7-fold, indicating the primary mode of glucose transport is still through GLUT4 (Fig. 4A,C). Downstream 
of GLUT4, however, we found rate limiting proteins of glycolysis and glycogen synthesis to be substantially 
decreased in nerve damaged muscle. PFK1, phosphorylating fructose 6-phosphate to fructose 1/6 bisphosphate 
during glycolysis, was decreased 2.1-fold in nerve damaged TA (Fig. 4A,C). This decrease in PFK1 was accompa-
nied by an equally great 2.1-fold decrease in GS, indicating that the increase in glucose concentrations found in 
the metabolomics data (Fig. 1B) is neither resulting in increased glycolysis nor glycogen storage. Finally, oxida-
tive metabolism as represented by total OXPHOS levels was decreased 2.4-fold, pointing to the fact that besides 
glycolysis and glycogen synthesis, mitochondrial activity in skeletal muscle appears to be negatively affected by 
chronic nerve constriction as well.
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Discussion
The main purpose of this study was to investigate the changes occurring to skeletal muscle metabolism with 
chronic nerve constriction injury and relate them back to findings in nerve transection and other neuromuscular 
diseases. We found that chronic constriction injury of the sciatic nerve in rats results in increased intramuscular 
glucose and polyol pathway intermediate concentrations. The transport of glucose appeared to be primarily medi-
ated through GLUT4, even though localization around the sarcolemma was scattered. The increase in glucose and 
GLUT4 was accompanied by a decrease in PFK1 and GS, indicating that glycolysis and glycogen synthesis are 
unable to process glucose at sufficient rates.
Figure 1. Untargeted metabolomics of rat TA four weeks after constriction injury to the sciatic nerve. (A) After 
annotation, 79 polar metabolites could be identified, 27 of which were significantly altered in nerve damaged 
TA (DMG) compared to the contralateral control leg of the same animals (CTRL). The heatmap summarizes 
all metabolites (only main products) which are significantly different between CTRL and DMG together with 
the corresponding effect size (d). Metabolites are sorted from low to high d. (B) Glucose was increased 2.6-
fold in DMG compared to CTRL (p < 0.007). (C) G6-P was decreased 1.9-fold, without reaching statistical 
significance due to high variability. (D) Sorbitol was increased 1.9-fold, but could not be analyzed statistically 
as the concentrations in 5 out of 7 animals in the control leg were below the threshold of detection. (E) Fructose 
was increased 1.7-fold in DMG compared to control (p < 0.005). Groups were compared via unpaired t-test, 
*indicates p < 0.05, **indicates p < 0.01.
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That neuromuscular diseases can affect skeletal muscle metabolism is long known4. For example, ALS has 
been shown to be accompanied by insulin resistance and accumulation of glucose and fructose in muscle samples 
of patients3. Interestingly, we have found IRS1 levels in our rats to be substantially decreased with nerve damage, 
while glucose and fructose concentrations were increased. Since ALS is defined as the progressive deterioration 
and eventual death of motor neurons, it is not inconceivable that the metabolic phenotype observed in skeletal 
muscle of these patients could be a function of nerve damage and shares certain characteristics with a peripheral 
nerve disorder such as the constriction injury in our model.
When compared to nerve transection previous research suggests a significant overlap with our data. Early 
research found that nerve transection induced insulin resistance and was accompanied by a decreased ability 
of skeletal muscle to take up glucose8. While this was further reflected by decreased glucose concentrations and 
GLUT4 levels7, more recent studies have indicated that this effect might be transient10. Callahan et al. have shown 
that transection of the sciatic nerve and the associated muscle loss in mice are followed by a decrease in GLUT4 
mRNA expression and an inability of insulin to stimulate glucose uptake 3 days after surgery10. However, at 28 
days post surgery, while continuing to lose muscle mass and cross sectional area, the mice still had decreased 
GLUT4 mRNA expression, but started to show increased GLUT4 protein levels and an improved ability to take 
up glucose with and without insulin10. This effect corresponds well with the timeline of our study and appears to 
become exacerbated over time, despite continuous muscle loss, as the group differences in the Callahan study fur-
ther increased at 56 days post surgery. While we have not tested insulin sensitivity directly, the decreased IRS1 
levels we found with nerve constriction injury in our rats might indicate slight differences to the aforemen-
tioned nerve transection study in mice. In spite of this, the authors have found the effect in increased glucose 
uptake and GLUT4 to coincide with increased total Akt and pAkt levels, which is in line with our findings as well 
(Fig. 4A,B).
It is important to point out that for GLUT4’s ability to modulate glucose uptake, localization at the sarco-
lemma had been shown to be of greater importance than protein abundance22. Since we have seen abundant, but 
scattered localization of GLUT4 with constriction injury to the nerve (Fig. 2), we were initially skeptical towards 
the ability of GLUT4 to function as an efficient glucose transporter in these animals. However, several lines of evi-
dence point to a sufficient and likely even increased uptake of glucose via GLUT4 in our model. The first impor-
tant indicator that GLUT4 is still the primary route of glucose transport is the decrease observed in GLUT1 levels 
in nerve damaged TA (Fig. 4A,C). These are the two most prevalent glucose transporter in skeletal muscle and the 
1.7-fold decrease in GLUT1 coincides with a 7.8-fold increase in GLUT4. Furthermore, two proteins downstream 
of glucose transport, specifically PFK1 and GS indicate a decrease in glycolysis and glycogen synthesis. This is 
in line with the metabolomics data, where we measured increased intramuscular glucose concentrations that 
were not accompanied by an increase in G6-P (Fig. 1A). Lastly, the evidence provided by a similar nerve damage 
model found an increase in GLUT4 that was associated with improved glucose uptake10. Therefore, glucose trans-
port into muscle affected by constriction injury to the nerve appears to be primarily governed through GLUT4, 
despite its scattered localization.
Figure 2. Altered GLUT4 localization in nerve damaged muscle. Nerve damage affected TA and controlateral 
control TA were sectioned and processed for immunohistochemical analysis of GLUT4. Stainings indicate 
that GLUT4 is more homogeneously located around the sarcolemma in healthy control muscle (white arrows), 
but scattered and aggregated in nerve damaged muscle with occasional accumulation in the perinuclear space 
(white arrows). Scale bars: 50 µm (left) and 10 µm (right).
6Scientific RepoRtS |         (2020) 10:1908  | https://doi.org/10.1038/s41598-020-58213-1
www.nature.com/scientificreportswww.nature.com/scientificreports/
Figure 3. Protein levels associated with membrane damage, cytoskeletal integrity, inflammation and autophagy 
are increased in nerve damaged TA, while oxidative activity appears to be decreased. Rat TA was subjected 
to western blot anaylsis of proteins associated with muscle damage. (A) Dysferlin, AnnexinA2, Cyclophilin, 
MLIM and LC3B are significantly upregulated in nerve damaged TA, while NOS (pan) levels are substantially 
decreased with nerve damage. (B) Bands corresponding to the western blot quantification in (A) (n = 5). 
The cropped pictures displayed above show the entire width of the membrane and all samples included for 
several different proteins. In order to allow for probing of multiple proteins with distinct molecular weight 
simultaneously, the membranes where cut horizontally at the appropriate heights. All band intensities were 
normalized to total protein content of the gel as assessed via coomassie blue staining. (C) Bands corresponding 
to the western blot quantification in (A) (n = 6). These blots were added during a later stage of the manuscript. 
All band intensities were normalized to total protein content of the gel as assessed via stain-free technology. 
*p < 0.05, **p < 0.01, ***p < 0.001.
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Figure 4. Altered protein levels associated with glucose metabolism and mitochondrial activity in nerve 
damaged TA. Rat TA was subjected to western blot anaylsis of proteins associated with glucose metabolism and 
oxidative metabolism. (A) IRS1 is downregulated, while total AKT is increased. Insulin independent GLUT4 
signaling via pAMPK is slightly increased as well. Glucose transporter GLUT4 is increased, while GLUT1 levels 
are decreased in nerve damage. The rate limiting proteins of glycolysis (PFK1) and glycogen synthesis (GS) are 
decreased with nerve damaged TA. Additionally, total oxidative phosphorylation of mitochondrial proteins is 
decreased in nerve damage. (B) Bands corresponding to the western blot quantification in (A) (n = 5). All band 
intensities were normalized to total protein content of the gel. (C) Bands corresponding to the western blot 
quantification in (A) (n = 6). These blots were added at a later stage of the manuscript. All band intensities were 
normalized to total protein content of the gel. *p < 0.05, **p < 0.01, ***p < 0.001.
8Scientific RepoRtS |         (2020) 10:1908  | https://doi.org/10.1038/s41598-020-58213-1
www.nature.com/scientificreportswww.nature.com/scientificreports/
Another disease sharing certain characteristics of a metabolic phenotype with our study, despite not being a 
neuromuscular disorder per se, is diabetes mellitus. Even though diabetes is defined by whole body insulin resist-
ance, skeletal muscle as the greatest glycogen depot of the human body has still a particularly great role in the 
development and progression of the disease. Several studies in diabetic mice and -men have shown increased 
polyol pathway activity in different tissues23. This increased activity of polyol pathway intermediates such as 
sorbitol and fructose were suggested to contribute to oxidative damage and eventually polyneuropathy in animals 
and patients24–26. In our study, we found decreased IRS1 signaling and increased concentrations of polyol path-
way intermediates sorbitol and fructose with nerve damage (Fig. 1A). Therefore we were intrigued whether this 
upregulated activity of the polyol pathway was associated with increased oxidative damage, potentially explaining 
part of the muscle loss we have seen in our animals previously12. Surprisingly, we found total NOS activity to be 
reduced >3-fold in nerve damaged TA (Fig. 3A,C). While we cannot conclusively discard the possibility that 
increased polyol pathway activity contributes to oxidative damage and muscle atrophy in our model, the decrease 
in total NOS makes it appear less likely and points towards a more physiological role of the polyol pathway.
Indeed, in another neurological disease associated with motor neuron damage, muscle atrophy and a met-
abolic phenotype, Charcot-Marie-Tooth disease (CMT), the polyol pathway intermediate sorbitol is currently 
tested in a phase III clinical trial as part of a combination of treatments for CMT type 1 A (NCT03023540). 
Previous data in animals and a phase II trial suggest a moderate effect on myelination and muscular perfor-
mance, particularly when sorbitol is used in conjunction with the other two treatment components (baclofen, 
naltrexone)27–29. While it seems unlikely that sorbitol alone would exhibit a substantial effect on disease pro-
gression and muscle loss for any neuromuscular disease, it does indicate that there could be a physiological and 
potentially even mildly beneficial role for sorbitol as a substrate in those conditions. Further supporting this 
notion, co-ingestion of sorbitol with glucose has recently shown improved blood glucose levels and muscle glu-
cose uptake ex vivo in healthy and diabetic rats compared to glucose ingestion alone30. If these findings turn out to 
be biologically relevant in humans, then alternative fuels could be an exciting avenue to pursue as an adjunct ther-
apeutic approach or at least for refined nutritional recommendations toward patients. Relating to the idea of alter-
native fuels for degenerating muscle, we have also found beta-hydroxybutyrate to be elevated in nerve damaged 
TA (Supplemental Fig. S1). Thus, the polyol pathway might not be the only interesting candidate to investigate.
While the underlying pathology causing the metabolic phenotype in diseases such as ALS, CMT, nerve tran-
section and nerve constriction could intuitively be attributed to gradual denervation, this common denominator 
is not present in other neuromuscular diseases that still share some of the same metabolic characteristics. For 
example, previous research has shown that dermatomyositis (DM) and its disease progression are at least par-
tially associated with increased dysferlin levels as well as increased polyol pathway activity31. Dysferlin is a large 
membrane protein and important for the integrity of the sarcolemma and injury repair32. We have found dysferlin 
and several other proteins with a role in muscle damage to be elevated in our model (Fig. 3A–C). Despite this 
correlation between increased dysferlin levels and polyol pathway activity, data obtained from dysferlin deficient 
mice and primary myoblasts from dysferlinopathy patients indicate certain similarities with the metabolic pheno-
type seen in our nerve damage model33. Interestingly, a similar pattern can be observed for Duchenne muscular 
dystrophy (DMD). While there are reports of impaired glucose uptake and increased insulin resistance in DMD 
patients34, a recent study in a golden retriever model for Duchenne (GRMD) has found decreased GLUT4 mRNA 
expression, but increased GLUT4 protein levels and glucose flux into GRMD skeletal muscle35. Therefore, skeletal 
muscle metabolism is evidently highly complex and whether the metabolic phenotype observed in our and other 
models of nerve damage is primarily a function of neurodegeneration or rather a symptom of muscle that under-
goes remodeling and atrophy is unclear. Indeed, we have shown that the metabolic phenotype we report here is 
also associated with increased myofibrillar protein synthesis and histopathological markers of muscle remodeling 
in the same animals12.
To conclude, peripheral nerve disorders, motor neuron diseases, inheritable neurological diseases and neu-
romuscular diseases share certain characteristics of deranged glucose metabolism. These include altered insulin 
sensitivity, GLUT4 expression, -translocation and protein levels, as well as increased glucose uptake into muscle. 
We have shown that chronic constriction injury to the sciatic nerve causes increased intramuscular glucose- and 
polyol pathway intermediate concentrations. While traditionally thought to be undesirable, the decrease of NOS 
levels in our model and the results of other recent studies suggest that there might be a physiological role for the 
polyol pathway in damaged muscle. The observed increase in glucose is not accompanied by increased G6-P, 
but by elevated levels of GLUT4 and a concomitant decrease of the rate limiting enzymes of glycolysis (PFK1) 
and glycogen synthesis (GS). Thus, glucose and fructose accumulation in nerve damaged muscle appear to be 
a combination of increased glucose uptake and decreased glycolytic activity. Future research needs to decipher 
whether these metabolic changes are caused by neurodegeneration or whether they are a common feature of 
muscle atrophy and remodeling.
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